Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: NRAS protein inhibitors - Parabilis Medicines

Next Previous
Drug Profile

Research programme: NRAS protein inhibitors - Parabilis Medicines

Alternative Names: NRAS (ON) - Parabilis Medicines

Latest Information Update: 14 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator FogPharma
  • Developer Parabilis Medicines
  • Class Antineoplastics; Peptides
  • Mechanism of Action NRAS protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 13 Dec 2022 Early research in Cancer in USA (unspecified route) (FogPharma pipeline, December 2022)
  • 31 Dec 2017 Harvard university licenses Helicon™ peptides technology to FogPharma prior to December 2017 (FogPharma website, March 2021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top